TORONTO, Jan. 18, 2023 (GLOBE NEWSWIRE) — Reunion Neuroscience Inc. (NASDAQ: REUN, TSX: REUN) (“Reunion” or “the Company”), a biopharmaceutical company committed to developing innovative and patented therapeutic solutions for underserved mental health conditions, announced today that it has appointed Robert Alexander, M.D. as the Company’s Chief Medical Officer, effective immediately. Dr.


Previous articleRick Doblin – The Balance at MAPS Between Public Benefit and Private Profit
Next articlePanel: Psychedelic VCs Reflect on 2022